Operating Income (Loss) in USD of Design Therapeutics, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Design Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q3 2025.
  • Design Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$19.3M, a 18.9% decline year-over-year.
  • Design Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$78M, a 28.3% decline year-over-year.
  • Design Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$62.4M, a 20.2% increase from 2023.
  • Design Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$78.2M, a 15.7% decline from 2022.
  • Design Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$67.6M, a 88.6% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

Design Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$78M -$19.3M -$3.07M -18.9% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 -$74.9M -$21.6M -$6.53M -43.4% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 -$68.4M -$20.4M -$6.02M -41.8% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 -$62.4M -$16.7M -$1.57M -10.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-10
Q3 2024 -$60.8M -$16.2M +$2.58M +13.7% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 -$63.4M -$15M +$7.55M +33.4% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 -$70.9M -$14.4M +$7.25M +33.5% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 -$78.2M -$15.1M +$4.27M +22% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-10
Q3 2023 -$82.5M -$18.8M +$370K +1.93% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$82.8M -$22.6M -$6.96M -44.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$75.9M -$21.7M -$8.28M -61.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$67.6M -$19.4M -$8.27M -74.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 -$59.3M -$19.2M -$7.86M -69.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$51.5M -$15.6M -$7.95M -103% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$43.5M -$13.4M -$7.69M -135% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$35.8M -$11.1M -$7.27M -188% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 -$28.6M -$11.3M -$8.95M -376% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$19.6M -$7.69M -$6.22M -425% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$13.4M -$5.68M -$5.06M -812% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$8.33M -$3.86M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$2.38M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$1.46M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$623K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10

Design Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$62.4M +$15.8M +20.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-10
2023 -$78.2M -$10.6M -15.7% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-10
2022 -$67.6M -$31.8M -88.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-19
2021 -$35.8M -$27.5M -330% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-14
2020 -$8.33M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.